MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBVX
CUSIPN/A
Phone858-259-9405
Debt
Debt-to-Equity Ratio1.48
Current Ratio0.21
Quick Ratio0.21
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales56.44
Cash FlowN/A
Price / CashN/A
Book Value$0.15 per share
Price / Book6.30
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-19,020,000.00
Net MarginsN/A
Return on Equity-2,767.01%
Return on Assets-199.42%
Miscellaneous
Employees11
Outstanding Shares8,960,000
Market Cap$10.31
Mabvax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions
What is Mabvax Therapeutics' stock symbol?
Mabvax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."
When did Mabvax Therapeutics' stock split? How did Mabvax Therapeutics' stock split work?
Mabvax Therapeutics's stock reverse split on the morning of Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of Mabvax Therapeutics stock prior to the reverse split would have 33 shares after the split.
How were Mabvax Therapeutics' earnings last quarter?
Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) announced its earnings results on Tuesday, November, 7th. The company reported ($1.62) earnings per share for the quarter. View Mabvax Therapeutics' Earnings History.
What is the consensus analysts' recommendation for Mabvax Therapeutics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mabvax Therapeutics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Mabvax Therapeutics' key competitors?
Some companies that are related to Mabvax Therapeutics include Xenetic Biosciences (XBIO), Q BioMed (QBIO), Chiasma (CHMA), Nemus Bioscience (NMUS), Onconova Therapeutics (ONTX), PLx Pharma (PLXP), ProPhase Labs (PRPH), BENITEC BIOPHAR/S (BNTC), NeuroVive Pharmaceutical (NEVPF), Ceapro (CRPOF), OvaScience (OVAS), SUMMIT THERAPEU/S (SMMT), Citius Pharmaceuticals (CTXR), Tonix Pharmaceuticals (TNXP) and AEterna Zentaris (AEZS).
Who are Mabvax Therapeutics' key executives?
Mabvax Therapeutics' management team includes the folowing people:
- Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
- Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
- Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, Chief Financial Officer (Age 71)
- Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
- Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)
Has Mabvax Therapeutics been receiving favorable news coverage?
Media headlines about MBVX stock have trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mabvax Therapeutics earned a news sentiment score of 0.11 on Accern's scale. They also gave news headlines about the company an impact score of 45.17 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Mabvax Therapeutics?
Shares of MBVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mabvax Therapeutics' stock price today?
One share of MBVX stock can currently be purchased for approximately $0.9449.
How big of a company is Mabvax Therapeutics?
Mabvax Therapeutics has a market capitalization of $10.31 million and generates $150,000.00 in revenue each year. Mabvax Therapeutics employs 11 workers across the globe.
How can I contact Mabvax Therapeutics?
Mabvax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]
MarketBeat Community Rating for Mabvax Therapeutics (NASDAQ MBVX)
MarketBeat's community ratings are surveys of what our community members think about Mabvax Therapeutics and other stocks. Vote "Outperform" if you believe MBVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
